Host |
Monospecific Mouse |
Klon |
ZM191 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human Ubiquitin protein fragment (around aa 1-119) |
Lokalisation |
Cytoplasm and Cell membrane |
Ubiquitin
|
Zeta Corporation |
ZM191 |
1 ml |
Concentrate |
CE/IVD |
Z2504ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM191 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human Ubiquitin protein fragment (around aa 1-119) |
Lokalisation |
Cytoplasm and Cell membrane |
Ubiquitin
|
Zeta Corporation |
ZM191 |
7 ml |
Ready-to-use |
CE/IVD |
Z2504MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM191 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human Ubiquitin protein fragment (around aa 1-119) |
Lokalisation |
Cytoplasm and Cell membrane |
Ubiquitin
|
Zeta Corporation |
ZM191 |
0.5 ml |
Concentrate |
CE/IVD |
Z2504MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM191 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human Ubiquitin protein fragment (around aa 1-119) |
Lokalisation |
Cytoplasm and Cell membrane |
Ubiquitin
|
Zeta Corporation |
ZM191 |
0.1 ml |
Concentrate |
CE/IVD |
Z2504MT |
-
|
Host |
Mouse+Rabbit |
Klon |
Ks20.8+EP9 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
p53 positive bladder or colon cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 and Rabbit IgG |
Lokalisation |
Nuclear (p53) and cytoplasmic (CK20) |
URO-2TM (Cytokeratin 20 + p53)
|
Biocare Medical |
Ks20.8+EP9 |
6 ml |
Ready-to-use |
CE/IVD |
API3001DSAA |
-
|
Host |
Mouse + Rabbit |
Klon |
156-3C11+EP9+Ks20.8 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Some bladder and colon carcinomas |
Verdünnung |
- |
Isotyp |
MouseIgG2a+RabbitIgG+MouseIgG2a |
Lokalisation |
Cytoplasm and nucleus |
URO-3 Triple StainTM (CD44 + Cytokeratin 20 + p53)
|
Biocare Medical |
156-3C11+EP9+Ks20.8 |
6 ml |
Ready-to-use |
CE/IVD |
PM370TSAA |
-
|
Host |
Mouse |
Klon |
ZM204 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bladder or urothelial carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ & IgG1/κ |
Verdünnung |
Recombinant fragment (around aa 114-173) of human Uroplakin 1A (UPK1A) protein. Recombinant fragment (around aa 109-229) of human Uroplakin 1B (UPK1B) |
Lokalisation |
Cytoplasm and Cell membrane |
Uroplakin
|
Zeta Corporation |
ZM204 |
1 ml |
Concentrate |
CE/IVD |
Z2522ML |
-
|
Host |
Mouse |
Klon |
ZM204 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bladder or urothelial carcinoma |
Verdünnung |
- |
Isotyp |
IgG2b/κ & IgG1/κ |
Verdünnung |
Recombinant fragment (around aa 114-173) of human Uroplakin 1A (UPK1A) protein. Recombinant fragment (around aa 109-229) of human Uroplakin 1B (UPK1B) |
Lokalisation |
Cytoplasm and Cell membrane |
Uroplakin
|
Zeta Corporation |
ZM204 |
7 ml |
Ready-to-use |
CE/IVD |
Z2522MP |
-
|
Host |
Mouse |
Klon |
ZM204 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bladder or urothelial carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ & IgG1/κ |
Verdünnung |
Recombinant fragment (around aa 114-173) of human Uroplakin 1A (UPK1A) protein. Recombinant fragment (around aa 109-229) of human Uroplakin 1B (UPK1B) |
Lokalisation |
Cytoplasm and Cell membrane |
Uroplakin
|
Zeta Corporation |
ZM204 |
0.5 ml |
Concentrate |
CE/IVD |
Z2522MS |
-
|
Host |
Mouse |
Klon |
ZM204 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bladder or urothelial carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ & IgG1/κ |
Verdünnung |
Recombinant fragment (around aa 114-173) of human Uroplakin 1A (UPK1A) protein. Recombinant fragment (around aa 109-229) of human Uroplakin 1B (UPK1B) |
Lokalisation |
Cytoplasm and Cell membrane |
Uroplakin
|
Zeta Corporation |
ZM204 |
0.1 ml |
Concentrate |
CE/IVD |
Z2522MT |
-
|
Host |
Rabbit |
Klon |
DBRRM3.66 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bladder |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Uroplakin 3Bprotein fragment (around aa 100-300) |
Lokalisation |
Membranous |
Uroplakin 3B
|
Diagnostic Biosystems |
DBRRM3.66 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB117R |
-
|
Host |
Rabbit |
Klon |
DBRRM3.66 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bladder |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Uroplakin 3Bprotein fragment (around aa 100-300) |
Lokalisation |
Membranous |
Uroplakin 3B
|
Diagnostic Biosystems |
DBRRM3.66 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB117R-01 |
-
|
Host |
Rabbit |
Klon |
DBRRM3.66 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bladder |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Uroplakin 3Bprotein fragment (around aa 100-300) |
Lokalisation |
Membranous |
Uroplakin 3B
|
Diagnostic Biosystems |
DBRRM3.66 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB117R-05 |
-
|
Host |
Rabbit |
Klon |
DBRRM3.66 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bladder |
Verdünnung |
--- |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Uroplakin 3Bprotein fragment (around aa 100-300) |
Lokalisation |
Membranous |
Uroplakin 3B
|
Diagnostic Biosystems |
DBRRM3.66 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD117R |
-
|
Host |
Mouse |
Klon |
BC21 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal bladder or urothelial carcinoma of the bladder |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human Uroplakin II protein |
Lokalisation |
Cytoplasm and cytoplasmic membrane |
Uroplakin II
|
Biocare Medical |
BC21 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3051A |
-
|
Host |
Mouse |
Klon |
BC21 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal bladder or urothelial carcinoma of the bladder |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human Uroplakin II protein |
Lokalisation |
Cytoplasm and cytoplasmic membrane |
Uroplakin II
|
Biocare Medical |
BC21 |
1 ml |
Concentrate |
CE/IVD |
ACI3051C |
-
|
Host |
Mouse |
Klon |
BC21 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal bladder or urothelial carcinoma of the bladder |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human Uroplakin II protein |
Lokalisation |
Cytoplasm and cytoplasmic membrane |
Uroplakin II
|
Biocare Medical |
BC21 |
6 ml |
Ready-to-use |
CE/IVD |
API3051AA |
-
|
Host |
Mouse |
Klon |
BC21 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Normal bladder or urothelial carcinoma of the bladder |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human Uroplakin II protein |
Lokalisation |
Cytoplasmic and membrane |
Uroplakin II
|
Biocare Medical |
BC21 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3051KG |
-
|
Host |
Mouse + Mouse |
Klon |
BC21 + BC17 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Urothelial carcinoma or normal bladder |
Verdünnung |
- |
Isotyp |
Mouse IgG1 + Mouse IgG1 |
Lokalisation |
Cytoplasmic membrane + cytoplasm |
Uroplakin II + Uroplakin III
|
Biocare Medical |
BC21 + BC17 |
6 ml |
Ready-to-use |
CE/IVD |
API3094AA |
-
|
Host |
Mouse |
Klon |
BC17 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Bladder cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, membrane |
Uroplakin III
|
Biocare Medical |
BC17 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3023A |
-
|
Host |
Mouse |
Klon |
BC17 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Bladder cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, membrane |
Uroplakin III
|
Biocare Medical |
BC17 |
1 ml |
Concentrate |
CE/IVD |
ACI3023C |
-
|
Host |
Mouse |
Klon |
BC17 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Bladder cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, membrane |
Uroplakin III
|
Biocare Medical |
BC17 |
6 ml |
Ready-to-use |
CE/IVD |
API3023AA |
-
|
Host |
Mouse |
Klon |
AU1 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Fast Enzyme or Citrate |
Positivkontrolle |
Urothial carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Urethelial surface membrane |
Uroplakin III
|
Zytomed Systems GmbH |
AU1 |
0.5 ml |
Concentrate |
RUO |
MSK052-05 |
-
|
Host |
Mouse |
Klon |
10A3 |
Format |
Purified |
Methode |
WB, IP |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant v-myb protein, DNA binding protein |
v-Myb/c-Myb
|
Zytomed Systems GmbH |
10A3 |
100 µg |
Purified |
RUO |
622-0074 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
F, P, IF |
Positivkontrolle |
Hypothalamus |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic arginine vasopressin conjugated to bovine thyroglobulin |
Vasopressin (Arg)
|
Zytomed Systems GmbH |
polyclonal |
50 µl |
Purified |
RUO |
622-0018 |
-
|
Host |
Goat |
Klon |
polyclonal |
Format |
Lyophilised |
Methode |
EL, WB |
Isotyp |
Goat IgG |
Verdünnung |
Recombinant human VEGF |
VEGF (Vascular Endothelial Growth Factor)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
622-0026 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
EDTA |
Positivkontrolle |
Hemangiosarcoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from N-terminal of human VEGF. |
Lokalisation |
Cytoplasmic, Cell surface, Extracellular matrix |
VEGF-A (Vascular Endothelial Growth Factor)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
522-2614 |
-
|
Host |
Rabbit |
Klon |
EP1176Y |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, some breast and ovarian cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Membrane or cytoplasmic |
VEGF-A (Vascular Endothelial Growth Factor)
|
Biocare Medical |
EP1176Y |
0.1 ml |
Concentrate |
CE/IVD |
ACI356AK |
-
|
Host |
Rabbit |
Klon |
EP1176Y |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, some breast and ovarian cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Membrane or cytoplasmic |
VEGF-A (Vascular Endothelial Growth Factor)
|
Biocare Medical |
EP1176Y |
0.5 ml |
Concentrate |
CE/IVD |
ACI356BK |
-
|
Host |
Mouse |
Klon |
VG1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Astrocytoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
VEGF-A (Vascular Endothelial Growth Factor)
|
Diagnostic Biosystems |
VG1 |
1 ml |
Concentrate |
CE/IVD |
MOB308 |
-
|
Host |
Mouse |
Klon |
VG1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Astrocytoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
VEGF-A (Vascular Endothelial Growth Factor)
|
Diagnostic Biosystems |
VG1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB308-01 |
-
|
Host |
Mouse |
Klon |
VG1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Astrocytoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
VEGF-A (Vascular Endothelial Growth Factor)
|
Diagnostic Biosystems |
VG1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB308-05 |
-
|
Host |
Mouse |
Klon |
VG1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Astrocytoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
VEGF-A (Vascular Endothelial Growth Factor)
|
Diagnostic Biosystems |
VG1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM165 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Angiosarcoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminal of human Flt-1. |
Lokalisation |
Cytoplasm |
VEGFr-1 (Flt-1)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
506-2804 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Angiosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
VEGFr-1 (Flt-1)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP077 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Angiosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
VEGFr-1 (Flt-1)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP077-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Angiosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
VEGFr-1 (Flt-1)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP077-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Angiosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
VEGFr-2 (Flk-1, KDR)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP076 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Angiosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
VEGFr-2 (Flk-1, KDR)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP076-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Angiosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
VEGFr-2 (Flk-1, KDR)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP076-05 |
-
|
Host |
Mouse |
Klon |
CH-11 |
Format |
Purified |
Methode |
P, WB, EL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Placenta |
Isotyp |
Mouse IgG1 |
Verdünnung |
Recombinant fragment corresponding to amino acids 1158 to 1345 (the intracellular region) of mouse VEGF receptor 2 |
VEGFr-2 (Flk-1)
|
Zytomed Systems GmbH |
CH-11 |
100 µg |
Purified |
RUO |
622-0029 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta, Breast Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human Flt-4. |
Lokalisation |
Cytoplasm, Cell Membrane |
VEGFr-3 (Flt-4)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
506-3874 |
-
|
Host |
Mouse |
Klon |
1D2C3 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Small intestine, Colorectal carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Apical membranous (brush border) / Cytoplasmic |
Villin
|
Diagnostic Biosystems |
1D2C3 |
1 ml |
Concentrate |
CE/IVD |
MOB590 |
-
|
Host |
Mouse |
Klon |
1D2C3 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Small intestine, Colorectal carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Apical membranous (brush border) / Cytoplasmic |
Villin
|
Diagnostic Biosystems |
1D2C3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB590-01 |
-
|
Host |
Mouse |
Klon |
1D2C3 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Small intestine, Colorectal carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Apical membranous (brush border) / Cytoplasmic |
Villin
|
Diagnostic Biosystems |
1D2C3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB590-05 |
-
|
Host |
Mouse |
Klon |
1D2C3 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Small intestine, Colorectal carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Apical membranous (brush border) / Cytoplasmic |
Villin
|
Diagnostic Biosystems |
1D2C3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM590 |
-
|
Host |
Rabbit |
Klon |
SP20 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
- |
Positivkontrolle |
Skin, Melanoma, Sarcoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant Protein corresponding to human vimentin |
Lokalisation |
Cytoplasm |
Vimentin
|
Zytomed Systems GmbH |
SP20 |
0.1 ml |
Concentrate |
RUO |
522-3200 |
-
|
Host |
Rabbit |
Klon |
SP20 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
- |
Positivkontrolle |
Skin, Melanoma, Sarcoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant Protein corresponding to human vimentin |
Lokalisation |
Cytoplasm |
Vimentin
|
Zytomed Systems GmbH |
SP20 |
0.5 ml |
Concentrate |
RUO |
522-3202 |
-
|
Host |
Rabbit |
Klon |
SP20 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
- |
Positivkontrolle |
Skin, Melanoma, Sarcoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant Protein corresponding to human vimentin |
Lokalisation |
Cytoplasm |
Vimentin
|
Zytomed Systems GmbH |
SP20 |
1 ml |
Concentrate |
RUO |
522-3204 |
-
|
Host |
Mouse |
Klon |
V9 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
Vimentin (V9)
|
Biocare Medical |
V9 |
6 ml |
Ready-to-use |
CE/IVD |
AVI048G |
-
|